Enclomiphene Citrate VA Coverage Pathway

Why Enclomiphene Is Not on the VA Formulary

Enclomiphene citrate, the trans-isomer of clomiphene, has never received standalone FDA approval. The VA National Formulary only lists drugs with an active New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA), which means compounded-only medications require a separate authorization pathway. Repros Therapeutics submitted an NDA for enclomiphene (branded as Androxal) targeting secondary hypogonadism, but the FDA issued a Complete Response Letter in 2015 citing concerns about assay methodology and the need for additional spermatogenesis data.

The VA Pharmacy Benefits Management (PBM) program reviews each formulary addition against clinical evidence, cost-effectiveness, and FDA regulatory status [1]. Without an approved NDA, enclomiphene cannot enter the standard formulary review cycle. This distinction matters: clomiphene citrate (which contains roughly 62% enclomiphene and 38% zuclomiphene) does appear on most VA facility formularies because it holds FDA approval for ovulation induction, and VA prescribers use it off-label for male hypogonadism [2].

A 2019 retrospective analysis of VA pharmacy records showed that clomiphene citrate prescriptions for male veterans increased 452% between 2010 and 2017, reflecting growing clinical interest in SERM-based testosterone restoration over exogenous testosterone [3]. That trend creates a practical opening. If your VA provider already prescribes clomiphene for hypogonadism, the clinical rationale for isolated enclomiphene (fewer estrogenic side effects from the zuclomiphene isomer) is straightforward to document on a nonformulary request.

The Nonformulary Drug Request Process

Getting enclomiphene through the VA requires a nonformulary drug request, formally called a "Nonformulary Consult" or "PACT Pharmacy Request" depending on the facility. Your prescribing physician submits this electronically through CPRS (Computerized Patient Record System). The request goes to the facility's Pharmacy and Therapeutics (P&T) Committee or a designated clinical pharmacist for review.

The request must include three elements: a documented diagnosis (ICD-10 code E29.1 for testicular hypofunction is standard), evidence that formulary alternatives were tried or are contraindicated, and a clinical rationale explaining why enclomiphene specifically is needed [4]. The strongest justification pairs two facts: the veteran has secondary hypogonadism confirmed by two morning total testosterone levels below 300 ng/dL (Endocrine Society 2018 guideline threshold), and the veteran wants to preserve spermatogenesis, which exogenous testosterone suppresses [5].

Approval rates vary by facility. Some VA medical centers approve compounded medications routinely when the prescriber documents formulary failure. Others require a formal trial of clomiphene citrate first, with documentation of side effects attributable to the zuclomiphene isomer (mood changes, visual disturbances, or elevated estradiol) before authorizing the isolated enclomiphene compound. Processing takes 5 to 14 business days at most sites.

If the nonformulary request is denied, veterans can appeal through the facility Patient Advocate or request a second review by the Chief of Pharmacy. The VA also allows veterans to use their Community Care (MISSION Act) benefit to fill prescriptions at outside compounding pharmacies if the VA cannot provide the medication in a timely manner, though this pathway requires prior authorization from the veteran's PACT (Patient Aligned Care Team).

What Enclomiphene Actually Costs Veterans

VA pharmacy copays operate on a tiered system that makes most medications significantly cheaper than retail. Veterans in Priority Groups 1 through 6 (which includes those with service-connected disabilities rated 50% or higher, former POWs, and veterans receiving VA pension) pay $0 for all outpatient medications [6]. Veterans in Priority Groups 7 and 8 pay $5 for a 30-day supply of generics and $11 for brand-name or compounded drugs.

That $5 to $11 copay applies regardless of the actual acquisition cost. For context, the VA's consolidated mail-order pharmacy (CMOP) acquires compounded medications through blanket purchase agreements with 503B outsourcing facilities registered with the FDA. A typical 30-day supply of enclomiphene 25 mg capsules costs the VA system between $15 and $40 wholesale, but the veteran's copay stays fixed at the tier rate.

Outside the VA, the economics shift considerably. Compounding pharmacies charge $60 to $120 per month for enclomiphene citrate, depending on dosage (12.5 mg vs. 25 mg), capsule count, and geographic location [7]. Telehealth men's health clinics that prescribe compounded enclomiphene typically add a consultation fee of $75 to $199 per visit. No manufacturer coupon exists for enclomiphene because there is no branded manufacturer product on the market. Discount cards like GoodRx do not index compounded medications.

One cost-saving comparison worth noting: a 2014 trial by Kaminetsky and colleagues found that enclomiphene 25 mg daily raised mean total testosterone from 228.8 ng/dL to 567.4 ng/dL at 6 months while maintaining sperm concentration above baseline [8]. Clomiphene citrate 25 mg (the VA formulary alternative) produces similar testosterone increases in most studies, with a 2020 meta-analysis in Fertility and Sterility reporting a weighted mean testosterone increase of 292 ng/dL across 15 studies [9]. The clinical question, then, is whether the side-effect profile of isolated enclomiphene justifies the added administrative burden of a nonformulary request.

Clomiphene vs. Enclomiphene: What the VA Formulary Alternative Offers

Clomiphene citrate sits on most VA facility formularies for off-label use in male hypogonadism. It costs the VA approximately $0.30 per 50 mg tablet through federal supply schedule pricing, making it one of the cheapest testosterone-restoring interventions available. A standard male dose of 25 mg every other day or 50 mg three times weekly costs under $5 per month at VA acquisition pricing.

The clinical difference between clomiphene and enclomiphene comes down to the zuclomiphene isomer. Zuclomiphene is an estrogen receptor agonist with a long half-life (approximately 30 days vs. 10 hours for enclomiphene). It accumulates with repeated dosing [10]. A pharmacokinetic study published in Clinical Pharmacology & Therapeutics showed that after 6 months of daily clomiphene, zuclomiphene serum concentrations were 7-fold higher than enclomiphene concentrations, raising estradiol levels and potentially contributing to mood disturbance, breast tenderness, and visual symptoms reported in 5% to 10% of male users [10].

For veterans who tolerate clomiphene well, the VA formulary version is the path of least resistance. Zero paperwork beyond a standard prescription. For veterans who develop estrogen-mediated side effects on clomiphene, documented intolerance creates the strongest possible nonformulary justification for switching to isolated enclomiphene.

Some VA endocrinologists take a middle approach: they prescribe clomiphene at lower doses (12.5 mg daily) combined with an aromatase inhibitor like anastrozole (0.5 mg twice weekly) to control estradiol. Anastrozole is on the VA formulary. This combination mimics some of enclomiphene's cleaner SERM profile without requiring a nonformulary request, though it adds a second medication and requires estradiol monitoring every 3 to 6 months.

Using VA Community Care to Fill Enclomiphene Externally

The VA MISSION Act (2018) expanded veterans' ability to receive care, including pharmacy services, from community providers when the VA cannot meet access or quality standards [11]. If a VA facility's pharmacy cannot compound or source enclomiphene, and the nonformulary request has been approved, the veteran may be eligible to fill the prescription at a community compounding pharmacy with VA covering the cost.

The process works like this. Your PACT team submits a community care referral. The VA's third-party administrator (currently Optum for most regions) authorizes the referral. You take the authorization and your VA prescription to a participating compounding pharmacy. The pharmacy bills the VA directly. Your copay stays at the standard VA tier rate.

Practical barriers exist. Not all compounding pharmacies are enrolled as VA community care providers. The veteran may need to call several pharmacies to find one that accepts VA community care authorization. Processing the referral can add 2 to 4 weeks on top of the nonformulary approval timeline.

A faster workaround: some veterans choose to pay cash at a compounding pharmacy ($60 to $120 per month) while the VA nonformulary process runs, then switch to VA pharmacy once approval comes through. This avoids treatment gaps. Keep all receipts. If the nonformulary request is ultimately approved, some VA facilities will reimburse interim out-of-pocket costs through the VA's Beneficiary Travel and Reimbursement office, though this is discretionary and not guaranteed.

Clinical Evidence Supporting the VA Prescribing Rationale

VA prescribers need evidence to justify nonformulary requests. Three studies anchor the clinical case for enclomiphene in male secondary hypogonadism.

The ZA-301 trial (N=173) randomized men with secondary hypogonadism to enclomiphene 12.5 mg, enclomiphene 25 mg, or topical testosterone gel. At 12 months, both enclomiphene arms maintained total testosterone above 450 ng/dL. Sperm concentrations remained stable in the enclomiphene groups but dropped by 42% in the testosterone gel group [8]. The ZA-302 trial (N=124) confirmed these findings over 6 months, with 83% of the 25 mg enclomiphene group achieving testosterone levels in the normal range (300 to 1,000 ng/dL) [12].

A 2022 systematic review published in Translational Andrology and Urology evaluated all available enclomiphene and clomiphene studies for male hypogonadism and concluded that enclomiphene "restores eugonadal testosterone while preserving or improving sperm parameters," rating the quality of evidence as moderate [13].

The Endocrine Society 2018 Clinical Practice Guideline recommends against testosterone therapy in men actively seeking fertility and suggests SERMs as an off-label alternative, noting that "clomiphene citrate has been used off-label to treat male infertility associated with secondary hypogonadism" [5]. The guideline does not specifically name enclomiphene (it was not yet widely compounded at the time of publication), but the pharmacologic rationale applies directly.

For VA prescribers preparing a nonformulary consult, citing the ZA-301 trial, the 2018 Endocrine Society guideline, and the documented zuclomiphene side-effect profile provides a three-legged clinical justification that most P&T committees will find sufficient.

Step-by-Step: Getting Enclomiphene Through the VA

A concrete sequence for veterans pursuing this pathway:

Step 1. Confirm your diagnosis. You need two morning total testosterone levels below 300 ng/dL drawn before 10:00 AM, plus LH and FSH levels in the low-normal or low range (indicating secondary rather than primary hypogonadism) [5]. Request these labs through your VA primary care provider.

Step 2. Get a specialty consult. Ask for a referral to VA endocrinology or urology. Specialists carry more weight in nonformulary requests than primary care prescribers at most facilities.

Step 3. Trial clomiphene first (if required by your facility). Some VA P&T committees require documentation that the formulary alternative was attempted. A 3-month trial of clomiphene citrate 25 mg daily with follow-up labs (total testosterone, estradiol, CBC) satisfies this requirement. Document any side effects in detail with your provider.

Step 4. Submit the nonformulary request. Your prescriber enters this through CPRS. The request should reference your testosterone levels, fertility goals, clomiphene trial results (if applicable), and cite at least one published study supporting enclomiphene efficacy.

Step 5. Wait for P&T review. Contact the pharmacy service after 10 business days if you have not received a decision. You have the right to request a written explanation of any denial.

Step 6. Fill the prescription. Once approved, your VA pharmacy will either compound the medication in-house (some VA facilities have compounding capabilities) or order it from a 503B outsourcing facility. If neither option is available, request community care pharmacy authorization.

The entire process from first lab draw to filled prescription typically takes 6 to 12 weeks when no appeal is needed.

Insurance Coverage Outside the VA

Veterans with dual coverage (VA plus private insurance or Medicare Part D) sometimes find it easier to access enclomiphene through their non-VA benefit. Private insurance does not cover enclomiphene any more consistently than the VA, since it lacks FDA approval, but some plans cover compounded medications under a pharmacy rider.

Check your plan's Summary of Benefits for "compounded medication" language. Plans administered by Express Scripts, CVS Caremark, and OptumRx have varying policies. Some cover compounded drugs at a specialty tier copay ($50 to $100). Most exclude them entirely [14]. A prior authorization from your prescriber may override the exclusion if the clinical justification is strong.

Medicare Part D does not cover compounded medications that contain a bulk drug substance not on the FDA's list of approved bulk substances for compounding. Enclomiphene citrate is currently available for compounding under section 503A, meaning individual prescriptions from a licensed compounding pharmacy are legal, but Part D formulary inclusion is not required.

Tricare (for veterans who are also military retirees) follows a similar pattern to commercial insurance. Compounded medications filled at non-network pharmacies are generally not covered. Tricare's home delivery pharmacy does not stock compounded enclomiphene.

The most reliable non-VA coverage pathway remains direct cash-pay at a compounding pharmacy. Prices have dropped from $150+ per month in 2022 to $60 to $90 per month at most national compounding pharmacies as of 2026, driven by increased prescribing volume and competition among telehealth platforms [7].